🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

✨ 🆕 #FGPodcast 🚨 alert ➡️ 👂Check out Oliver Tavabie interview Scott Isaacs ➕ Paul Brennan on the "Role of anti-diabetic medications in the management of MASLD" 🔗 Link to 📻 #FGPodcast ⬇️ and relevant article 📰 bit.ly/3FALQDe ▶️ Apple: apple.co/3SXaUr5 ▶️

EASL has released new CPGs on abdominal extrahepatic surgery in patients with cirrhosis and advanced chronic liver disease at #EASLCongress—a critical step in improving surgical outcomes for this high-risk population. 🏥🩺 🔍 Why it matters: As non-hepatic abdominal surgeries

📣New data on cirrhosis recompensation in Journal of Hepatology ✅Only 7% meets strict Baveno VII criteria ✅Expanded criteria capture ~38% with similar low mortality risk Recompensation: ⬇️systemic inflammation🔥 👍 improved hemodynamic ⬆️improved survival doi.org/10.1016/j.jhep…

💪Sarcopenia isn’t just a muscle condition, it’s a major health risk. Our new paper, link.springer.com/article/10.100… "Health outcomes of sarcopenia: a consensus report by the outcome working group of the Global Leadership Initiative in Sarcopenia (GLIS)" brings together a global team

Review Portal sinusoidal vascular diseases: Assessment and therapy Mironova et al. #LiverX tinyurl.com/56yde2p9

People often ask me: do you recommend NON-ALCOHOLIC BEER to patients that continue to drink regular beer? Although it can be a practical solution, it has two risks: - It predicts returning to alcoholic beverages. - This paper shows that its sugar content is metabolically bad.

📢Interested in MOC? Check out this review article by Hassan et al Liver #transplantation for pediatric genetic & metabolic disorders #livertransplant #pediatrictransplant

🧬 Breaking: Regeneron may have just improved upon basic GLP-1 weight loss therapy - - - New Phase 2 COURAGE trial top-line data suggest that combining semaglutide (Wegovy/Ozempic) with muscle-preserving antibodies could dramatically improve the quality of weight loss—not just

İyi Bayramlar! Gönüllerin bir olduğu, sevginin paylaşıldığı, umutların yeşerdiği bir bayram geçirmeniz dileğiyle… Sevdiklerinizle birlikte sağlık, huzur ve mutluluk dolu bir Kurban Bayramı dileriz. 💛 #İyiBayramlar #KurbanBayramı #SevgiyleBayram #BayramınRuhu

📢New EAS Consensus Statement – Systemic Metabolic Disorder as a Unified Clinical Entity. Published in European Heart Journal (2025) The European Atherosclerosis Society introduces a clinically actionable, pathophysiology-based 3-stage classificationof Systemic Metabolic Disorder (SMD) — a

Our new paper on Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with MASH: a randomised, phase 2a trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa… Manuel Romero-Gómez Daniel Huang Naim Alkhouri Mazen Noureddin, MD, MHSc Quentin M. Anstee Christopher A. Longhurst, MD

Benefits of 1 kg Weight Loss Through Lifestyle Changes 1️⃣ HDL-C: +1.44% 2️⃣ Triglycerides: −1.37% 3️⃣ Insulin: −2.46% 4️⃣ HOMA-IR: −2.71% 5️⃣ Liver Fat: −0.49% 6️⃣ Systolic Blood Pressure: −0.26% 7️⃣ Diastolic Blood Pressure: −0.36% Gil Carvalho MD PhD🌈 Dr. Spencer Nadolsky Karl Nadolsky

Advances in the treatment of ANCA-associated vasculitis ⏩high-dose steroids + rituximab/cyc works but causes side effects ⏩Rituximab is better than Aza ⏩Avacopan with RTX or cyc and low-dose steroids improves outcomes ⏩ CAR-T: promising nature.com/articles/s4158…

MASH with F2+ fibrosis is silently killing millions. This paper calls for DOUBLING diagnosis rates by 2027—using AI, NITs, and primary care. A paradigm shift is within reach. #MASLD #Hepatology #Publichealth Jeffrey V. Lazarus Paula Iruzubieta Sociedad Española de Patología Digestiva (SEPD) thelancet.com/journals/lanep…